Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy

LA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced it has entered into an engagement agreement with Digital Offering LLC, a FINRA- and SEC-registered broker-dealer, to serve as its exclusive placement agent in connection with the company's evaluation of a potential strategic capital raise.

This engagement supports Liminatus's previously disclosed review of a digital asset treasury strategy, as the company evaluates modern financial tools to strengthen its capital structure. The funding initiative may involve various exempt financing structures, including—but not limited to—convertible debentures, equity-linked securities, or other alternative instruments that comply with applicable U.S. securities laws.

Under this engagement agreement, Digital Offering is engaged to assist the company in sourcing institutional and digital asset–focused investors and structuring a compliant financing solution.

"At Liminatus, our core mission is advancing transformative immunotherapies for cancer," said Chris Kim, CEO of Liminatus. "As we work toward that goal, we are also taking proactive steps to strengthen our capital strategy. Partnering with Digital Offering allows us to explore strategic funding opportunities—both in traditional markets and the evolving digital asset landscape—with discipline and foresight."

Liminatus emphasizes that the engagement of Digital Offering relates strictly to placement agent services. No financing ...